Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

WINT

Windtree Therapeutics Inc

Jul 26 • 04:00PM ET

8.29

Dollar change +5.00
Percentage change 151.98	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-38.45	Insider Own	13.42%	Shs Outstand	0.51M	Perf Week	129.64%
Market Cap	4.23M	Forward P/E	-	EPS next Y	-2.13	Insider Trans	0.00%	Shs Float	0.44M	Perf Month	157.45%
Income	-5.96M	PEG	-	EPS next Q	-0.54	Inst Own	0.72%	Short Float	10.70%	Perf Quarter	63.51%
Sales	0.00M	P/S	-	EPS this Y	97.48%	Inst Trans	-	Short Ratio	0.77	Perf Half Y	2.94%
Book/sh	30.23	P/B	0.27	EPS next Y	10.50%	ROA	-18.26%	Short Interest	0.05M	Perf Year	-67.34%
Cash/sh	5.00	P/C	1.66	EPS next 5Y	-	ROE	-53.10%	52W Range	2.81 - 30.06	Perf YTD	-35.94%
Dividend Est.	-	P/FCF	-	EPS past 5Y	66.05%	ROI	-36.22%	52W High	-72.42%	Beta	0.54
Dividend TTM	-	Quick Ratio	0.67	Sales past 5Y	-37.79%	Gross Margin	-	52W Low	195.02%	ATR (14)	0.74
Dividend Ex-Date	-	Current Ratio	0.67	EPS Y/Y TTM	96.01%	Oper. Margin	0.00%	RSI (14)	86.80	Volatility	21.31% 10.78%
Employees	15	Debt/Eq	0.10	Sales Y/Y TTM	-	Profit Margin	-	Recom	3.00	Target Price	18.00
Option/Short	No / No	LT Debt/Eq	0.07	EPS Q/Q	125.63%	Payout	-	Rel Volume	787.75	Prev Close	3.29
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	May 15	Avg Volume	61.47K	Price	8.29
SMA20	137.69%	SMA50	134.48%	SMA200	-9.96%	Trades		Volume	48,423,094	Change	151.98%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-26-20	Initiated	Ladenburg Thalmann	Buy	$12.25

Today 07:36AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +151.98%
Jul-25-24 08:00AM	Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data (GlobeNewswire) -10.60%
Jul-22-24 04:05PM	Windtree Therapeutics Announces Closing of Financing Through a Private Placement of Series C Preferred Stock (GlobeNewswire)
May-24-24 07:16AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +7.73%
May-07-24 08:00AM	Windtree Therapeutics Regains Compliance with Nasdaq (GlobeNewswire) -9.74%
08:00AM	Loading…
Apr-18-24 08:00AM	Windtree Therapeutics Announces Reverse Stock Split (GlobeNewswire) -15.32%
Apr-17-24 08:00AM	Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates (GlobeNewswire)
06:52AM	WINT Stock Earnings: Windtree Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
Apr-08-24 04:48PM	Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing (GlobeNewswire) -9.51%
Feb-01-24 08:00AM	Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research (GlobeNewswire)
Jan-31-24 08:00AM	Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives (GlobeNewswire) -6.60%
Jan-26-24 09:20AM	Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company (ACCESSWIRE)
Jan-25-24 08:30AM	Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company (GlobeNewswire)
Jan-18-24 09:00AM	Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China (ACCESSWIRE)
Jan-17-24 08:00AM	Windtree Therapeutics Announces License Agreement with Lees Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region (GlobeNewswire) -18.04%
04:05PM	Loading…
Jan-02-24 04:05PM	Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator (GlobeNewswire) -10.61%
Dec-19-23 09:30AM	Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024 (ACCESSWIRE)
Dec-18-23 08:00AM	Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock (GlobeNewswire)
Nov-16-23 08:00AM	Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent (GlobeNewswire)
Nov-14-23 08:55AM	Sidoti Events, LLCs Virtual November Micro-Cap Conference (ACCESSWIRE)
Nov-09-23 04:15PM	Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates (GlobeNewswire)
Nov-08-23 08:00AM	Windtree to Present at the Sidoti Micro Cap Conference on November 16th (GlobeNewswire)
Oct-12-23 07:30AM	Windtree to Present at the ThinkEquity Conference on October 19th in New York City (GlobeNewswire) +18.42%
Oct-10-23 07:30AM	Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17th (GlobeNewswire)
Oct-03-23 08:00AM	Windtree to Present at the Dawson James Small Cap Growth Conference on October 12th (GlobeNewswire)
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire)
Aug-25-23 07:20AM	7 F-Rated Biotech Stocks You Shouldnt Touch With a 10-Foot Pole (InvestorPlace) -7.02%
Aug-23-23 08:00AM	Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators by the US Patent and Trademark Office (GlobeNewswire)
Aug-16-23 09:00AM	Windtree Therapeutics (NASDAQ:WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar Market (ACCESSWIRE)
Aug-07-23 04:05PM	Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates (GlobeNewswire) +6.82%
09:25AM	Loading…
Jul-25-23 09:25AM	Windtree Therapeutics' (NASDAQ: WINT) Upcoming Istaroxime Development Milestones And Next Generation Drug Candidates Could Produce New Fast Follow-On Line Of Drugs For Heart Failure (ACCESSWIRE)
Jul-18-23 09:00AM	The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market (ACCESSWIRE)
Jul-14-23 09:00AM	Medical Management Of Deadly Urgent Cardiogenic Shock Largely Remains A Challenge Windtree Therapeutics (NASDAQ:WINT) Is Helping Change That (ACCESSWIRE)
Jun-27-23 08:00AM	Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors (GlobeNewswire)
Jun-12-23 08:00AM	Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a Group of SERCA2a Activators with a Dual Mechanism (GlobeNewswire) -5.08%
Jun-05-23 08:00AM	Windtree Therapeutics to Host Virtual R&D and Investor Day Focusing on the Cardiogenic Shock Market, Istaroxime, Company Strategy and Planned Near-Term Milestones (GlobeNewswire) +8.63%
May-15-23 04:30PM	Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates (GlobeNewswire)
May-11-23 12:20PM	10 Best Stocks to Buy for a Quick Return (Insider Monkey)
Apr-27-23 08:00AM	Windtree Therapeutics Announces Publication from Its SEISMiC Pre Cardiogenic Shock Study Comparing Two Doses of Istaroxime (GlobeNewswire)
Apr-24-23 04:01PM	Windtree Therapeutics Announces Closing of $12.42 Million Underwritten Public Offering Including Full Exercise of Overallotment Option (GlobeNewswire) -12.26%
Apr-20-23 08:30AM	Windtree Therapeutics Announces Pricing of Upsized $10.8 Million Underwritten Public Offering (GlobeNewswire) -57.68%
Apr-17-23 08:00AM	Windtree Therapeutics Announces Issuance of New Dual Mechanism SERCA2a Activator Patent (GlobeNewswire) +88.81%
Apr-03-23 07:35AM	Windtree Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Key Business Updates (GlobeNewswire)
Mar-13-23 08:00AM	Windtree Regains Compliance with Nasdaq (GlobeNewswire)
Mar-06-23 08:00AM	Windtree Finds Cardiogenic Shock Has High Cost of US Patient Care and Plans Innovation with the Unique Profile of Istaroxime (GlobeNewswire)
Feb-28-23 08:00AM	Windtree Announces Publication on its SERCA2a Activator Drug Candidate for Chronic and Acute Heart Failure (GlobeNewswire)
Feb-27-23 08:00AM	Windtree Announces Istaroxime Scientific Abstract Has Been Accepted at the 2023 Technology and Heart Failure Therapeutics Conference (GlobeNewswire) -8.99%
Feb-24-23 08:00AM	Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office (GlobeNewswire) -15.85%
Feb-23-23 12:00PM	Windtree Therapeutics Announces Reverse Stock Split (GlobeNewswire) -34.40%
Jan-20-23 08:37AM	Windtree Therapeutics to Raise $1.0 Million From the Exercise of Previously Issued Warrants (GlobeNewswire) -25.65%
Dec-05-22 07:30AM	Nasdaq Grants Windtree Therapeutics 180-day Extension to Regain Compliance (GlobeNewswire) -5.43%
Nov-18-22 12:00PM	Windtree Therapeutics, Inc. (WINT) Upgraded to Buy: Here's Why (Zacks)
Nov-14-22 07:30AM	Windtree Therapeutics Reports Third Quarter 2022 Financial Results and Provides Key Business Updates (GlobeNewswire)
Oct-25-22 08:00AM	Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent (GlobeNewswire)
Oct-06-22 06:50AM	Multiple insiders bought Windtree Therapeutics, Inc. (NASDAQ:WINT) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
Sep-29-22 07:45AM	Windtree Therapeutics Stock Surges After Positive Istaroxime Data In Cardiogenic Shock (Benzinga) +6.15%
Sep-28-22 04:05PM	Windtree Therapeutics Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (SEISMiC) Published in the European Journal of Heart Failure (GlobeNewswire)
Sep-26-22 08:00AM	Windtree Therapeutics Announces Istaroxime Late Breaker Abstract from its Positive Phase 2 Study in Early Cardiogenic Shock (SEISMiC) to be Presented at Heart Failure Society of America (GlobeNewswire)
Sep-21-22 04:05PM	Windtree to Present at the Ladenburg Thalmann Healthcare Conference (GlobeNewswire) -6.13%
Sep-06-22 04:05PM	Windtree to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-24-22 02:59PM	Windtree Therapeutics out-licenses surfactant platform in a deal that could be worth nearly $80M (American City Business Journals) -28.14%
Aug-23-22 08:00AM	Windtree Therapeutics Announces KL4 Surfactant and AEROSURF® Global License Agreement (GlobeNewswire) +52.21%
Aug-11-22 04:05PM	Windtree Therapeutics Reports Second Quarter 2022 Financial Results and Provides Key Business Updates (GlobeNewswire)
Jun-29-22 08:00AM	Windtree Is Leveraging Positive Istaroxime Early Cardiogenic Shock Results to Proactively Engage in Licensing Discussions and Explore Strategic Opportunities to Realize Greater Shareholder Value (GlobeNewswire)
May-23-22 10:12AM	Windtree Presents Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock in a Late-Breaker Presentation at the European Society of Cardiology Heart Failure Meeting in Madrid (GlobeNewswire) -11.25%
May-16-22 07:00AM	Windtree Announces Conference Call to Present Data from its Positive SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock (GlobeNewswire) +6.82%
May-05-22 04:05PM	Windtree Therapeutics Reports First Quarter 2022 Financial Results and Provides Key Business Updates (GlobeNewswire) -7.75%
Apr-20-22 04:05PM	Windtree Therapeutics Announces Late-Breaker Presentation on Phase 2 SEISMiC Study Results of Istaroxime in Early Cardiogenic Shock at the European Society of Cardiology (ESC) Heart Failure Conference (GlobeNewswire) -14.63%
07:00AM	Windtree Announces Positive Topline Results from Its Phase 2 SEISMiC Study of Istaroxime in Early Cardiogenic Shock (GlobeNewswire)
Mar-31-22 04:05PM	Windtree to Participate in the Lytham Partners Spring 2022 Investor Conference (GlobeNewswire)
03:26PM	Insiders who purchased Windtree Therapeutics, Inc. (NASDAQ:WINT) stock last year recover some losses which currently stand at US$47k (Simply Wall St.)
07:05AM	Windtree Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Key Business Updates (GlobeNewswire)
Mar-22-22 01:47PM	Windtree Posts Mid-Stage Study Data On Lucinactant For COVID-19-Associated Respiratory Distress (Benzinga)
07:30AM	Windtree Announces Results from Its Phase 2 Study of Lucinactant for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) and Lung Injury (GlobeNewswire)
Mar-15-22 12:06PM	Windtree Therapeutics Concludes Enrollment In Mid-Stage Cardiogenic Shock Study, Data Expected In April (Benzinga)
07:00AM	Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock (GlobeNewswire)
Mar-10-22 08:00AM	Windtree to Present at Oppenheimers 32nd Annual Healthcare Conference (GlobeNewswire)
Feb-01-22 02:36PM	Why Are Windtree Therapeutics Shares Trading Higher Today? (Benzinga) +15.93%
07:30AM	Windtree Completes Enrollment in Its Phase 2 Study of Lucinactant (KL4 Surfactant) for COVID-19 Associated Lung Injury and Acute Respiratory Distress Syndrome (GlobeNewswire)
Dec-15-21 08:00AM	Windtree Announces U.S. Patent and Trademark Office Issuance of New U.S. Istaroxime Patent (GlobeNewswire)
Nov-22-21 04:59PM	2 Moonshot Biotechs with 10x Potential (InvestorPlace) +11.26%
08:00AM	Research Finds U.S. Cardiogenic Shock Patients Have High Hospital Inpatient Mortality and Long Length of Stay Adding to Previously Reported Need for New Pharmacologic Innovation (GlobeNewswire)
Nov-10-21 04:05PM	Windtree Therapeutics Reports Third Quarter 2021 Financial Results and Provides Key Business Updates (GlobeNewswire)
Oct-26-21 10:33AM	3 Moonshot Stocks Insiders Are Buying and 2 That Are Getting Dumped (InvestorPlace)
08:51AM	2 Penny Stocks Insiders Are Buying (Benzinga)
Oct-25-21 07:30AM	Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent (GlobeNewswire)
Oct-20-21 07:36AM	3 Penny Stocks Insiders Are Buying (Benzinga) +5.79%
Oct-14-21 07:30AM	Windtree Hosting Key Opinion Leader Webinar on Istaroxime for the Treatment of Acute Heart Failure and the Upcoming Data in Early Cardiogenic Shock (GlobeNewswire)
Oct-12-21 07:30AM	Market Research Finds 99% Of US Clinical Cardiologists Surveyed Report a High Unmet Need for New Innovative Drug Treatments for Early Cardiogenic Shock Patients (ECS) as Windtree Therapeutics Prepares for Clinical Results from its Istaroxime ECS Study (GlobeNewswire)
Sep-30-21 02:25PM	Multiple insiders bought Windtree Therapeutics, Inc. (NASDAQ:WINT) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
Sep-16-21 07:30AM	Windtree to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit (GlobeNewswire)
Aug-05-21 04:01PM	Windtree Therapeutics Reports Second Quarter 2021 Financial Results and Provides Key Business Updates (GlobeNewswire) -10.40%
Aug-02-21 08:00AM	Windtree Appoints Randall White, Ph.D., as Vice President, Clinical Program Management (GlobeNewswire)
Jul-08-21 11:20AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE)
07:30AM	Windtree to Present at Access to Giving Virtual Investor Conference (GlobeNewswire)
Jul-07-21 07:30AM	Windtree to Present at the Ladenburg Thalmann 2021 Healthcare Conference (Virtual) (GlobeNewswire)
Jul-01-21 07:30AM	Windtree Appoints Diane Carman, Esq. as Senior Vice President and General Counsel (PR Newswire)
Jun-23-21 09:35AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE) +5.16%
Jun-09-21 06:40AM	Most Shareholders Will Probably Agree With Windtree Therapeutics, Inc.'s (NASDAQ:WINT) CEO Compensation (Simply Wall St.)
May-13-21 07:30AM	Windtree Therapeutics Reports First Quarter 2021 Financial Results and Provides Key Business Updates (PR Newswire) -15.15%

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. It focuses on the treatment of acute cardiovascular and acute pulmonary diseases. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fraser Craig	President and CEO	Sep 27 '23	Buy	1.02	2,500	2,550	57,877	Sep 28 07:24 AM
Fraser Craig	President and CEO	Sep 26 '23	Buy	0.90	2,500	2,250	55,377	Sep 27 07:34 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

WINT

Windtree Therapeutics Inc

Upgrade your FINVIZ experience